CCCC Stock Overview
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
C4 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.87 |
| 52 Week High | US$11.88 |
| 52 Week Low | US$3.61 |
| Beta | 2.93 |
| 1 Month Change | -7.64% |
| 3 Month Change | -34.30% |
| 1 Year Change | -35.82% |
| 3 Year Change | -88.23% |
| 5 Year Change | n/a |
| Change since IPO | -84.82% |
Recent News & Updates
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06Recent updates
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04Shareholder Returns
| CCCC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | -3.3% | -0.4% |
| 1Y | -35.8% | -2.7% | 24.8% |
Return vs Industry: CCCC underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: CCCC underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| CCCC volatility | |
|---|---|
| CCCC Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCCC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CCCC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 145 | Andrew Hirsch | www.c4therapeutics.com |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
C4 Therapeutics, Inc. Fundamentals Summary
| CCCC fundamental statistics | |
|---|---|
| Market cap | US$273.18m |
| Earnings (TTM) | -US$105.50m |
| Revenue (TTM) | US$33.67m |
8.1x
P/S Ratio-2.6x
P/E RatioIs CCCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCCC income statement (TTM) | |
|---|---|
| Revenue | US$33.67m |
| Cost of Revenue | US$108.52m |
| Gross Profit | -US$74.85m |
| Other Expenses | US$30.65m |
| Earnings | -US$105.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | -222.31% |
| Net Profit Margin | -313.34% |
| Debt/Equity Ratio | 0% |
How did CCCC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:19 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
C4 Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Matthew Luchini | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |